image
Healthcare - Biotechnology - NASDAQ - US
$ 1.36
-6.85 %
$ 6.09 M
Market Cap
-0.01
P/E
CASH FLOW STATEMENT
-8.27 M OPERATING CASH FLOW
7.32%
-147 K INVESTING CASH FLOW
0.00%
3.65 M FINANCING CASH FLOW
1826112.50%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Alzamend Neuro, Inc.
image
Net Income -9.95 M
Depreciation & Amortization 50.7 K
Capital Expenditures -147 K
Stock-Based Compensation 956 K
Change in Working Capital 671 K
Others 671 K
Free Cash Flow -8.42 M

Cash Flow

Millions
Apr-2024 Apr-2023 Apr-2022 Apr-2021 Apr-2020 Apr-2019 Apr-2018 Apr-2017 Apr-2016
OPERATING CASH FLOW
Net Income (9.9) (14.9) (12.4) (5.0) (4.4) (4.9) (0.9) (1.6) 69.5 K
Depreciation & Amortization 50.7 K 23.1 K 3.55 K 0 0 0 0 0 0
Deferred Income Tax 0 (1.7) 0 0 0 0 0 0 0
Stock Based Compensation 1.0 3.6 4.4 2.0 1.8 0.4 0.2 0.1 41 K
Other Operating Activities 714 1.7 8.77 K 0.5 0.6 2.2 0.2 88.5 K 15.6 K
Change in Working Capital 0.7 2.3 1.3 (0.2) (0.3) 1.2 (1.3) 49.7 K 5.63 K
Cash From Operations (8.3) (8.9) (6.6) (2.7) (2.3) (1.0) (2.1) (1.4) 18.5 K
INVESTING CASH FLOW
Capital Expenditures (0.1) 0 (0.1) 0 0 0 0 0 0
Other Items 0 0 0 0.1 0.1 0.2 (0.4) 0 0
Cash From Investing Activities (0.1) 0 (0.1) 0.1 0.1 0.2 (0.4) 0 0
FINANCING CASH FLOW
Common Stock Repurchased 0 0 0 0 0 0 0 0 0
Total Debt Repaid 0.3 0 0 0.4 0 0 (0.4) 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0
Other Financing Activities 5.5 200 18.9 4.0 2.3 72.7 K (0.3) 1.4 25.3 K
Cash From Financing Activities 3.7 200 18.9 4.5 2.3 0.3 3.0 1.4 25.3 K
CHANGE IN CASH
Net Change In Cash (4.8) (8.9) 12.1 1.8 47.7 K (0.5) 0.5 3.84 K 6.85 K
FREE CASH FLOW
Free Cash Flow (8.4) (8.9) (6.7) (2.7) (2.3) (1.0) (2.1) (1.4) 18.5 K